keyword
MENU ▼
Read by QxMD icon Read
search

Telbivudine

keyword
https://www.readbyqxmd.com/read/28884132/renal-function-improvement-by-telbivudine-in-liver-transplant-recipients-with-chronic-kidney-disease
#1
Wei-Chen Lee, Tsung-Han Wu, Yu-Chao Wang, Chih-Hsien Cheng, Chen-Fang Lee, Ting-Jung Wu, Hong-Shiue Chou, Kun-Ming Chan, Ching-Song Lee
Chronic renal failure is a frequent complication in liver transplantation. Telbivudine, anti-hepatitis B virus (HBV) nucleoside, can improve renal function. It is interesting if using telbivudine for prophylaxis of HBV recurrence has additional value on renal function improvement. 120 liver transplant recipients with lamivudine prophylaxis for HBV recurrence were 1 : 1 randomized into lamivudine-continuous (n = 60) and telbivudine-replacement (n = 60) groups. Fifty-eight patients in lamivudine-continuous group and 54 in telbivudine-replacement group completed the study...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28834607/association-of-baseline-vitamin-d-level-with-genetic-determinants-and-virologic-response-in-patients-with-chronic-hepatitis-b
#2
Rui Yu, Deming Tan, Qin Ning, Junqi Niu, Xuefan Bai, Shijun Chen, Jun Cheng, Yanyan Yu, Hao Wang, Min Xu, Guangfeng Shi, Mobin Wan, Xinyue Chen, Hong Tang, Jifang Sheng, Xiaoguang Dou, Junping Shi, Hong Ren, Maorong Wang, Hongfei Zhang, Zhiliang Gao, Chengwei Chen, Hong Ma, Jidong Jia, Jinlin Hou, Qing Xie, Jian Sun
AIM: The role of vitamin D in individuals with chronic hepatitis B (CHB) is unclear. We aimed to explore the association of baseline vitamin D level with genetic determinants and week-104 treatment outcome in CHB patients. METHODS: Baseline serum 25-hydroxycholecalciferol [25(OH)D] levels and genetic polymorphism within GC, DHCR7 and CYP2R1 were determined in stored serum of 560 patients who were enrolled into a multicenter, randomized, controlled study and completed the 104-week telbivudine monotherapy or telbivudine-based optimized therapy...
August 23, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28757867/factors-related-to-significant-improvement-of-estimated-glomerular-filtration-rates-in-chronic-hepatitis-b-patients-receiving-telbivudine-therapy
#3
Te-Fu Lin, Ping-I Hsu, Kung-Hung Lin, Feng-Woei Tsay, Tzung-Jiun Tsai, Yan-Hua Chen, Hsien-Chung Yu
BACKGROUND AND AIM: The improvement of estimated glomerular filtration rates (eGFRs) in chronic hepatitis B (CHB) patients receiving telbivudine therapy is well known. The aim of this study was to clarify the kinetics of eGFRs and to identify the significant factors related to the improvement of eGFRs in telbivudine-treated CHB patients in a real-world setting. METHODS: Serial eGFRs were calculated every 3 months using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28654554/baseline-hepatitis-b-virus-titer-predicts-initial-postpartum-hepatic-flare-a-multicenter-prospective-study
#4
Jinfeng Liu, Jing Wang, Caijing Qi, Furong Cao, Zhen Tian, Dandan Guo, Taotao Yan, Qian Li, Shujuan Yang, JianJun Fu, Xianmei Tang, Xiaoni Kou, Na Liu, Zicheng Jiang, Yingren Zhao, Tianyan Chen
BACKGROUND AND GOALS: A series of changes in the immune system occur during pregnancy and puerperium. Currently, we aim to characterize both the natural changes in liver inflammation and its association with hepatitis B viremia during this special period. PATIENTS AND METHODS: Chronic hepatitis B (CHB) gravidas were recruited and followed up to 52 weeks postpartum. Virological and biochemical parameters were assessed throughout the period. RESULTS: A total of 1097 CHB mothers had finished the entire follow-up including 451 accepting telbivudine, 178 accepting tenofovir, and 468 without antiviral therapy...
June 26, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28639033/functional-restoration-of-cd56-bright-nk-cells-facilitates-immune-control-via-il-15-and-nkg2d-in-patients-under-antiviral-treatment-for-chronic-hepatitis-b
#5
Tao Chen, Lin Zhu, Aichao Shi, Lin Ding, Xiaoping Zhang, Zhenmin Tan, Wei Guo, Weiming Yan, Meifang Han, Jidong Jia, Xiaoping Luo, Detlef Schuppan, Qin Ning
BACKGROUND AND AIMS: Hepatitis B virus (HBV) is intrinsically immunogenic, with long-lasting immune control in many patients. However, the mechanisms and key cell types underlying effective immune control are incompletely understood. METHODS: We studied the restoration of natural killer (NK) cell numbers and function post antiviral treatment in 52 hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients who received telbivudine (LdT) for 48 weeks...
June 20, 2017: Hepatology International
https://www.readbyqxmd.com/read/28603234/what-to-start-with-in-first-line-treatment-of-chronic-hepatitis-b-patients-an-italian-multicentre-observational-cohort-hbv-rer-study-group
#6
Gianluca Cuomo, Vanni Borghi, Tiziana Giuberti, Pietro Andreone, Marco Massari, Erica Villa, Antonello Pietrangelo, Gabriella Verucchi, Fabio Levantesi, Carlo Ferrari
Treatment options for chronic hepatitis B (CHB) are pegylated interferon (Peg-IFN) in minimal-mild liver fibrosis and nucleot(s)ide analogues (NUC) in more advanced disease. Since little is known about their use in daily clinical practice, we conducted a multicentre prospective study to investigate treatment regimens applied to naïve CHB patients in real life. HBV-RER is an observational multicentre Italian network that collect clinic and virologic data of patients with CHB. Among the 2527 CHB patients seen during the study period (2009 - 2012), 502 patients started a first line antiviral treatment...
June 1, 2017: Le Infezioni in Medicina
https://www.readbyqxmd.com/read/28591041/relationship-of-treg-th17-balance-with-hbeag-change-in-hbeag-positive-chronic-hepatitis-b-patients-receiving-telbivudine-antiviral-treatment-a-longitudinal-observational-study
#7
Xiaoling Yang, Jia Li, Jie Liu, Min Gao, Li Zhou, Wei Lu
Telbivudine (LdT) is an orally L-nucleoside with potent and specific antihepatitis B virus (HBV) activity. The higher rate of hepatitis B e antigen (HBeAg) seroconversion of LdT treatment than other anti-HBV agents suggests a potential immunomodulatory effect. The aim of the study was to investigate the changes of regulatory T cell (Treg)/interleukin (IL)-17-producing CD4+T helper (Th17) balance during LdT treatment and to discuss the relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B (CHB) patients receiving LdT antiviral treatment...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28562554/effectiveness-of-entecavir-or-telbivudine-therapy-in-patients-with-chronic-hepatitis-b-virus-infection-pre-treated-with-interferon-compared-with-de-novo-therapy-with-entecavir-and-telbivudine
#8
COMPARATIVE STUDY
Shaohang Cai, Jiawei Cao, Tao Yu, Muye Xia, Jie Peng
Little is known about the optimal treatment following the initial failure of interferon therapy and the potential different efficacy with de novo therapy with entecavir (ETV) or telbivudine (LDT) and following the interferon therapy failure.ETV or LDT therapy following the interferon therapy failure was compared with that of de novo therapy with ETV or LDT in patients with chronic hepatitis B virus (HBV) infection. Treatment parameters included virological response, hepatitis B e antigen (HBeAg) seroconversion, and alanine aminotransferase (ALT) normalization...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28551372/clinical-course-and-perinatal-transmission-of-chronic-hepatitis-b-during-pregnancy-a-real-world-prospective-cohort-study
#9
Zhi-Xian Chen, Gui-Fang Gu, Zhao-Lian Bian, Wei-Hua Cai, Yi Shen, Yan-Li Hao, Sheng Zhang, Jian-Guo Shao, Gang Qin
OBJECTIVE: To determine the clinical course and perinatal transmission of chronic hepatitis B during pregnancy in a real life setting. METHODS: A total of 221 singleton pregnant women with detectable HBV-DNA levels (≥10(3) copies/mL) were enrolled during January 2011 to June 2015. Forty-three high viraemic patients (≥10(6) copies/mL) received telbivudine in the 2(nd) or 3(rd) trimester according to their intention, while 89 high viraemic and 79 low viraemic (≥10(3) and <10(6) copies/mL) patients were the control cohorts...
May 24, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28539842/a-review-of-antiviral-use-for-the-treatment-of-chronic-hepatitis-b-virus-infection-in-pregnant-women
#10
Ariel Jaffe, Robert S Brown
Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) remains high even with the proper use of active-passive immunoprophylaxis in newborns. Mothers with significant viremia are at a much higher risk of MTCT; therefore, treatments aimed at lowering HBV DNA levels during pregnancy may ultimately decrease global disease burden. The exact threshold for treatment remains controversial; however, most studies have accepted levels greater than 2 × 5 log10 IU/mL as significant viremia. We reviewed the most recent literature on antiviral efficacy, maternal and fetal safety, and viral resistance patterns when used for short-duration therapy in pregnancy...
March 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28522916/early-hepatitis-b-viral-dna-clearance-predicts-treatment-response-at-week-96
#11
Xiao-Yu Fu, De-Ming Tan, Cui-Mei Liu, Bin Gu, Li-Hua Hu, Zhong-Tian Peng, Bin Chen, Yuan-Lin Xie, Huan-Yu Gong, Xiao-Xuan Hu, Lian-Hui Yao, Xiao-Ping Xu, Zheng-Yuan Fu, Lang-Qiu He, Si-Hai Li, Yun-Zhu Long, De-Hui Li, Ji-Long Gu, Shi-Fang Peng
AIM: To investigate whether hepatitis viral DNA load at 24 wk of treatment predicts response at 96 wk in patients with chronic hepatitis B. METHODS: A total of 172 hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B patients who received initial treatment at 16 tertiary hospitals in Hunan Province, China were enrolled in this study. All patients received conventional doses of lamivudine and adefovir dipivoxil, telbivudine, entecavir dispersible tablets, or entecavir tablets for 96 wk...
April 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28478758/-rhabdomyolysis-associated-with-telbivudin-therapy-report-of-a-case
#12
Almudena Mancebo González, María José Peñalver Jara, Laura Menéndez Naranjo, Ana Patricia Navarro Egea
No abstract text is available yet for this article.
May 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28445403/detection-of-hepatitis-b-virus-m204i-mutation-by-quantum-dot-labeled-dna-probe
#13
Cheng Zhang, Yiping Chen, Xinmiao Liang, Guanhua Zhang, Hong Ma, Leng Nie, Yu Wang
Quantum dots (QDs) are semiconductor nanoparticles with a diameter of less than 10 nm, which have been widely used as fluorescent probes in biochemical analysis and vivo imaging because of their excellent optical properties. Sensitive and convenient detection of hepatitis B virus (HBV) gene mutations is important in clinical diagnosis. Therefore, we developed a sensitive, low-cost and convenient QDs-mediated fluorescent method for the detection of HBV gene mutations in real serum samples from chronic hepatitis B (CHB) patients who had received lamivudine or telbivudine antiviral therapy...
April 26, 2017: Sensors
https://www.readbyqxmd.com/read/28434087/hepatitis-b-during-pregnancy-in-endemic-areas-screening-treatment-and-prevention-of-mother-to-child-transmission
#14
REVIEW
Naichaya Chamroonkul, Teerha Piratvisuth
The proper management of pregnant women infected with hepatitis B virus (HBV) is necessary to prevent maternal and fetal morbidity and mortality and to protect the baby from HBV infection. In the majority of cases, vertical transmission can be prevented with a universal screening program, HBV vaccine immunoprophylaxis, and administration of hepatitis B immunoglobulin (HBIg) for babies born to mothers with HBV. However, in mothers with a high viral load (>200,000 or >1,000,000 IU/ml, depending on the guideline), the chance of immunoprophylaxis failure remains high...
June 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28422442/effect-of-hepatitis-b-virus-subgenotype-on-antiviral-response-in-nucleoside-treated-hepatitis-b-envelope-antigen-positive-patients
#15
Sheng Shen, Xieer Liang, Kamal Hamed, Yasuhito Tanaka, Katsumi Omagari, Rong Fan, Qing Xie, Deming Tan, Bin Zhou, Ji-Dong Jia, Jinlin Hou, Jian Sun
AIM: Previous studies have reported that hepatitis B virus (HBV) genotype is not a predictor of treatment response with nucleos(t)ide analog therapy. However, the impact of subgenotype on treatment response is unknown. The aim of this study is to identify the effect of HBV subgenotype on treatment response. METHODS: In this retrospective study, the derivation dataset comprised patients from the EFFORT study (NCT00962533) telbivudine monotherapy group; patients infected with genotypes B or C from the GLOBE (NCT00057265) and 015 (NCT00131742) studies formed the validation dataset...
April 19, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28407735/telbivudine-treatment-started-in-early-and-middle-pregnancy-completely-blocks-hbv-vertical-transmission
#16
Weihui Sun, Shangfei Zhao, Lei Ma, Anhua Hao, Bo Zhao, Lin Zhou, Fengzhu Li, Mingquan Song
BACKGROUND: To evaluate the efficacy and safety of treating HBV-positive mothers with telbivudine in early and middle pregnancy to prevent mother-to-infant HBV transmission. METHODS: The subject population comprised pregnant women with chronic hepatitis B (CHB; n = 188) from January 2013 to June 2015, with HBV DNA ≥1.0 × 10(7)copies/mL and increased alanine aminotransferase levels. Groups A (n = 62) and B (n = 61) were treated with telbivudine starting at 12 weeks or 20-28 weeks after gestation, respectively...
April 13, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28386259/elevated-expression-of-chemokine-cxcl13-in-chronic-hepatitis-b-patients-links-to-immune-control-during-antiviral-therapy
#17
Chao Liu, Xuan Huang, Melanie Werner, Ruth Broering, Jun Ge, Yongyin Li, Baolin Liao, Jian Sun, Jie Peng, Mengji Lu, Jinlin Hou, Xiaoyong Zhang
C-X-C-chemokine ligand 13 (CXCL13), the ligand for C-X-C chemokine receptor type 5 (CXCR5), is a major regulator of B-cell trafficking and plays an integral role in age-dependent clearance of hepatitis B virus (HBV) in the mouse model. However, the expression and function of CXCL13 in patients with chronic hepatitis B (CHB) remain unknown. By use of liver cell subpopulations isolated from CHB patients, we found that CXCL13 mRNA was abundantly expressed in Kupffer cells (KCs), but not in primary hepatocytes, liver sinusoidal endothelial cells, and hepatic stellate cells...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28373116/telbivudine-attenuates-gentamicin-induced-kidney-injury-in-rats
#18
Cigdem Kader, Mustafa Sunbul, Yavuz Kursad Das, Murat Yarim, Abdulkerim Bedir, Efe Karaca, Mehmet Celikbilek, Resat Ozaras
Nephrotoxicity has been associated with nucleos(t)ide analogues other than telbivudine (LdT). This study investigated the potential effects of LdT and lamivudine (LAM) on renal function in an experimental rat model of gentamicin-induced acute nephrotoxicity. A total of 28 healthy Wistar albino rats were randomly divided into four experimental groups: negative control; positive control (PC); LdT; and LAM. Nephrotoxicity was induced by gentamicin in the LdT, LAM and PC groups. LdT and LAM were administered to two groups for 6 weeks starting on the ninth day...
May 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28351603/predictors-of-hbeag-seroconversion-after-long-term-nucleos-t-ide-analogues-treatment-for-chronic-hepatitis-b-a-multicenter-study-in-real-clinical-setting
#19
Weiyan Yu, Yadong Wang, Chuan Shen, Ru Ji, Li Zhang, Xin Zhao, Miao Su, Ying Zhang, Wenyan He, Jianguo Cao, Yanshuang Hao, Shengpeng Chen, Caiyan Zhao
AIMS: To evaluate the HBeAg seroconversion rate in real clinical setting and explore its predictors in long-term nucleos(t)ide analogues (NAs) treatment for chronic hepatitis B (CHB). METHODS: 251 patients were recruited from January 2001 to September 2009 in four hospitals in Hebei province, China, for this retrospective study. Clinical and laboratory data before and after treatment with lamivudine (LAM, 100mg daily), adefovir (ADV, 10mg daily), telbivudine (LDT, 600mg daily), entecavir (ETV, 0...
March 27, 2017: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28345181/hbsag-kinetics-during-treatment-with-nucleos-t-ides-analogues-in-patients-with-hbeag-negative-chronic-hepatitis-b
#20
Athanasia Striki, Spilios Manolakopoulos, Melanie Deutsch, Anastasia Kourikou, George Kontos, Hariklia Kranidioti, Emilia Hadziyannis, George Papatheodoridis
BACKGROUND/AIMS: Serum HBsAg levels might be used as predictor of virological breakthrough or of sustained off-treatment virological response in HBeAg-negative chronic hepatitis B (CHB) patients. We evaluated the changes of HBsAg in those patients under nucleos(t)ide analogue(s) [NA(s)] therapy for ≥12 months. METHODS: We included 99 HBeAg-negative CHB patients treated with low-genetic barrier NA(s) for a mean of 66 months (lamivudine: 66, adefovir: 6, lamivudine plus adefovir: 11, telbivudine: 16) and 86 HBeAg-negative CHB patients under entecavir or tenofovir for a mean of 30 months as the comparison group...
March 26, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
2108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"